GAMMA Investing LLC Sells 1,204 Shares of Progyny, Inc. $PGNY

GAMMA Investing LLC decreased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 22.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,175 shares of the company’s stock after selling 1,204 shares during the period. GAMMA Investing LLC’s holdings in Progyny were worth $92,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC bought a new position in shares of Progyny in the 1st quarter valued at about $354,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of Progyny by 18.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 34,675 shares of the company’s stock valued at $775,000 after acquiring an additional 5,459 shares during the last quarter. Voya Investment Management LLC lifted its stake in Progyny by 258.2% in the first quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock worth $4,144,000 after purchasing an additional 133,703 shares during the last quarter. Millennium Management LLC lifted its stake in Progyny by 7.5% in the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock worth $29,107,000 after purchasing an additional 90,367 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its stake in Progyny by 243.6% in the first quarter. Acadian Asset Management LLC now owns 205,650 shares of the company’s stock worth $4,589,000 after purchasing an additional 145,802 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Down 3.2%

Shares of PGNY stock opened at $20.55 on Friday. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 34.83, a PEG ratio of 1.80 and a beta of 1.34. The company’s 50 day moving average is $22.64 and its 200 day moving average is $22.26. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $26.76.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.23). The business had revenue of $332.87 million for the quarter, compared to analysts’ expectations of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insider Activity at Progyny

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the transaction, the director directly owned 12,501 shares of the company’s stock, valued at approximately $275,522.04. The trade was a 16.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares in the company, valued at $1,829,843.12. This represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,895 shares of company stock worth $179,311. 9.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on PGNY. Truist Financial raised their price objective on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. Raymond James Financial set a $28.00 price objective on shares of Progyny in a research note on Friday, August 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Finally, Canaccord Genuity Group raised their price objective on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $25.44.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.